Proteomic Characterization of the Gastric Cancer Response to Chemo- and Targeted therapies Reveals Axis of the Immune and Metabolic Pathways

Herein, we set out to investigate the responses to first-line therapies (DOS, XELOX, and anti-HER2-based therapies) for GC through a comprehensive proteomic analysis. We constructed a GC cohort that covered three clinical therapy subcohorts, including a DOS subcohort (44 patients treated with DOS therapy), an XELOX subcohort (70 patients treated with XELOX therapy) and a HER2 subcohort (71 patients who received anti-HER2-based therapy).